Internal Medicine, Endocrinology, Diabetes, & Metabolism · Oroville, CA
NPI
1467892984
Since 2013
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
2450 Oro Dam Blvd E
Oroville, CA, 95966
Phone (530) 990-7430
Groups this clinician bills Medicare through
Medicare paid, 2024
$133K
1,527 services
Medicare patients, 2024
711
Average age 71
Drug cost, 2024
$3.6M
6,269 prescriptions
Company payments, 2025
$244
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Yewande Adepoju was code 99214 (office e&m - established), 828 times for 395 patients. In total Yewande Adepoju billed 1,527 services in 13 codes, and Medicare paid $133K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-10-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 828 | 395 | $95.46 | $79K |
| 99213 Office E&M - Established | Office | 483 | 280 | $66.33 | $32K |
| 99204 Office E&M - New | Office | 145 | 145 | $124.02 | $18K |
By year: 2022 $132K for 1,462 services; 2023 $134K for 2,194 services; 2024 $133K for 1,527 services.
Medicare prescription drug claims, 2024
In 2024, the drug Yewande Adepoju prescribed most often to Medicare patients was Ozempic (Semaglutide), with 975 prescriptions and refills. In total Yewande Adepoju wrote 6,269 Medicare prescriptions that cost $3.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 975 | 1,192 | 168 | $1.1M |
| Levothyroxine Sodium Generic | 498 | 1,112 | 134 | $4,741 |
| Jardiance Empagliflozin | 439 | 762 | 106 | $419K |
| Mounjaro Tirzepatide | 316 | 358 | 56 | $364K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 289 | 517 | 87 | $46K |
| Metformin Hcl Generic | 229 | 609 | 83 | $2,002 |
| Trulicity Dulaglutide | 217 | 288 | 56 | $271K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 178 | 323 | 46 | $81K |
| Humalog Kwikpen U-100 Insulin Lispro | 149 | 207 | 43 | $38K |
| Metformin Hcl Er Metformin Hcl | 138 | 359 | 44 | $1,278 |
| Ultra-Fine Short Pen Needle Pen Needle, Diabetic | 122 | 227 | 43 | $11K |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 113 | 202 | 40 | $11K |
| Novolog Flexpen Insulin Aspart | 105 | 171 | 51 | $27K |
| Glipizide Generic | 103 | 250 | 34 | $611 |
| Farxiga Dapagliflozin Propanediol | 100 | 150 | 27 | $80K |
Brand drugs: 3,987 claims; generic drugs: 1,748 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Yewande Adepoju $244 ($244 in general payments such as food, travel and fees) from 6 companies. The largest payer was Novo Nordisk Inc with $71.6.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.